Dolors Colomer

List of Publications by Year
in descending order

237	19,914	15466 65	11581 135
papers	citations	h-index	g-index

241	241	241	22441
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Insights into the mechanisms underlying aberrant SOX11 oncogene expression in mantle cell lymphoma. Leukemia, 2022, 36, 583-587.	3.3	5
2	Balanced and unbalanced translocations in a multicentric series of 2843 patients with chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2022, 61, 37-43.	1.5	10
3	Clinicoâ€biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation. British Journal of Haematology, 2022, 196, 146-155.	1.2	17
4	Natural killer cell receptors and ligand variants modulate response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Hla, 2022, 99, 93-104.	0.4	3
5	European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. Blood Advances, 2022, 6, 1193-1206.	2.5	26
6	Serum soluble CD23 levels are an independent predictor of time to first treatment in chronic lymphocytic leukemia. Hematological Oncology, 2022, 40, 588-595.	0.8	0
7	Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study. Leukemia, 2022, 36, 1834-1842.	3.3	10
8	Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy. Leukemia, 2022, 36, 1879-1886.	3.3	5
9	Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis. Journal of Hepatology, 2021, 74, 89-95.	1.8	25
10	Reply to: Correspondence on â€œNext-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosisâ€• Journal of Hepatology, 2021, 74, 252-254.	1.8	0
11	Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation. Nature Communications, 2021, 12, 651.	5.8	67
12	EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4+ T cells in chronic lymphocytic leukemia. Leukemia, 2021, 35, 2311-2324.	3.3	27
13	EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia. Leukemia, 2021, 35, 3152-3162.	3.3	26
14	The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma. Leukemia, 2021, 35, 2635-2649.	3.3	32
15	Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3081-3089.	1.2	14
16	Challenges with Approved Targeted Therapies against Recurrent Mutations in CLL: A Place for New Actionable Targets. Cancers, 2021, 13, 3150.	1.7	1
17	Advantages and disadvantages of mouse models of chronic lymphocytic leukemia in drug discovery. Expert Opinion on Drug Discovery, 2021, 16, 1085-1090.	2.5	1
18	Clinicobiological Characteristics and Outcomes of Patients with T-Cell Large Granular Lymphocytic Leukemia and Chronic Lymphoproliferative Disorder of Natural Killer Cells from a Single Institution. Cancers, 2021, 13, 3900.	1.7	12

#	Article	IF	Citations
19	Clonal relationship in multisited mucosaâ€associated lymphoid tissue lymphomas: a singleâ€centre experience. British Journal of Haematology, 2021, 192, 1020-1025.	1.2	1
20	Prognostic Impact of MYD88 L265P Mutation By Droplet Digital PCR in IgM MGUS and Smoldering WaldenstrÃ¶m Macroglobulinemia. Blood, 2021, 138, 462-462.	0.6	3
21	Interleukin-10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ TÂcell population that sustains anti-tumor immunity. Immunity, 2021, 54, 2825-2841.e10.	6.6	57
22	Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia. Leukemia, 2020, 34, 100-114.	3.3	31
23	Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells. Oncogene, 2020, 39, 1185-1197.	2.6	22
24	Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. Haematologica, 2020, 105, 1032-1041.	1.7	29
25	TBETâ€expressing Th1 CD4⁺T cells accumulate in chronic lymphocytic leukaemia without affecting disease progression in EÂµâ€TCL1 mice. British Journal of Haematology, 2020, 189, 133-145.	1.2	11
26	Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia. Journal of Molecular Diagnostics, 2020, 22, 1217-1224.	1.2	5
27	PI3KÎ´ inhibition reshapes follicular lymphomaâ€“immune microenvironment cross talk and unleashes the activity of venetoclax. Blood Advances, 2020, 4, 4217-4231.	2.5	23
28	Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia. Scientific Reports, 2020, 10, 22153.	1.6	16
29	Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease. Blood Advances, 2020, 4, 5652-5665.	2.5	67
30	Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease. British Journal of Haematology, 2020, 191, 52-61.	1.2	28
31	Chronic lymphocytic leukaemia and prolymphocytic leukaemia. Two coins or two sides of the same coin?. Haematologica, 2020, 105, e484.	1.7	2
32	IgCaller for reconstructing immunoglobulin gene rearrangements and oncogenic translocations from whole-genome sequencing in lymphoid neoplasms. Nature Communications, 2020, 11, 3390.	5.8	24
33	Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood, 2020, 136, 1419-1432.	0.6	131
34	Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. Haematologica, 2020, 105, 2205-2217.	1.7	47
35	Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma. Haematologica, 2019, 104, 778-788.	1.7	17
36	Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis. Annals of Hematology, 2019, 98, 2319-2328.	0.8	13

#	Article	IF	Citations
37	Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy. Journal of Experimental and Clinical Cancer Research, 2019, 38, 446.	3.5	28
38	Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia. International Journal of Cancer, 2019, 144, 2762-2773.	2.3	8
39	Early Tâ€cell precursor lymphoblastic leukaemia: response to <scp>FLAG</scp>â€<scp>IDA</scp> and highâ€dose cytarabine with sorafenib after initial refractoriness. British Journal of Haematology, 2019, 185, 755-757.	1.2	5
40	Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia. Haematologica, 2019, 104, 576-586.	1.7	40
41	Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues. Leukemia, 2019, 33, 625-637.	3.3	55
42	Eomes and IL-10 Regulate Anti-Tumor Activity of T Cells in Chronic Lymphocytic Leukemia. Blood, 2019, 134, 4288-4288.	0.6	0
43	The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia. Leukemia and Lymphoma, 2018, 59, 2318-2326.	0.6	5
44	Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA. Journal of Hematology and Oncology, 2018, 11, 112.	6.9	26
45	Cyclin D1 overexpression induces global transcriptional downregulation in lymphoid neoplasms. Journal of Clinical Investigation, 2018, 128, 4132-4147.	3.9	31
46	Targeting IRAK4 Disrupts Inflammatory Pathways and Delays Tumor Development in Chronic Lymphocytic Leukemia. Blood, 2018, 132, 2650-2650.	0.6	0
47	Triple Negative Myelofibrosis and Myelodysplastic Syndrome with Fibrosis: Clinico-Biological Characterization and Correlation with Gene Mutations. Blood, 2018, 132, 4299-4299.	0.6	0
48	Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1 Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Measurable Residual Disease (MRD): Results of a Preemptive Intervention Policy (CETLAM-2012 Protocol). Blood, 2018, 132, 1385-1385.	0.6	1
49	Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12Âyears follow-up of a phase 2 trial. Annals of Hematology, 2017, 96, 639-646.	0.8	7
50	Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study. Journal of Hepatology, 2017, 67, 501-507.	1.8	50
51	The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2017, 23, 2831-2841.	3.2	123
52	Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier. Haematologica, 2017, 102, e360-e363.	1.7	27
53	Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia. British Journal of Haematology, 2017, 178, 764-771.	1.2	22
54	An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2059-2066.	1.2	6

#	Article	IF	Citations
55	Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma. British Journal of Haematology, 2017, 177, 557-561.	1.2	14
56	The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-Î¹B mutational status. Haematologica, 2017, 102, e447-e451.	1.7	18
57	New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia. Expert Opinion on Drug Discovery, 2017, 12, 1041-1052.	2.5	3
58	Impact of the functional CD5 polymorphism A471V on the response of chronic lymphocytic leukaemia to conventional chemotherapy regimens. British Journal of Haematology, 2017, 177, 147-150.	1.2	8
59	Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response. Annals of Hematology, 2017, 96, 81-85.	0.8	28
60	The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemiaâ€“Microenvironment Interactions in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2017, 23, 1493-1505.	3.2	38
61	Cellular Ontogeny and Hierarchy Influence the Reprogramming Efficiency of Human B Cells into Induced Pluripotent Stem Cells. Stem Cells, 2016, 34, 581-587.	1.4	18
62	Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood, 2016, 127, 2122-2130.	0.6	260
63	NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive Disease. American Journal of Surgical Pathology, 2016, 40, 192-201.	2.1	40
64	MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome. Clinical Cancer Research, 2016, 22, 2755-2764.	3.2	55
65	CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia. Oncotarget, 2016, 7, 5507-5520.	0.8	23
66	Detection of chromothripsisâ€like patterns with a custom array platform for chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2015, 54, 668-680.	1.5	23
67	Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature, 2015, 526, 519-524.	13.7	749
68	Fluorescent Nucleoside Derivatives as a Tool for the Detection of Concentrative Nucleoside Transporter Activity Using Confocal Microscopy and Flow Cytometry. Molecular Pharmaceutics, 2015, 12, 2158-2166.	2.3	8
69	Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype. Modern Pathology, 2015, 28, 1435-1447.	2.9	35
70	Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis. Journal of Hepatology, 2015, 62, 72-74.	1.8	72
71	The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia. Oncotarget, 2015, 6, 22734-22749.	0.8	60
72	Bcl-2highmantle cell lymphoma cells are sensitized to acadesine with ABT-199. Oncotarget, 2015, 6, 21159-21172.	0.8	16

#	Article	IF	Citations
73	Gene Expression Profiling Signatures Allow the Identification of Unclassifiable Leukemic B-Cell Lymphoid Neoplasms. Blood, 2015, 126, 3902-3902.	0.6	0
74	4-Amino-2-arylamino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies. European Journal of Medicinal Chemistry, 2014, 86, 664-675.	2.6	26
75	In vivo intratumoral Epsteinâ€“Barr virus replication is associated with XBP1 activation and early-onset post-transplant lymphoproliferative disorders with prognostic implications. Modern Pathology, 2014, 27, 1599-1611.	2.9	22
76	The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy. Haematologica, 2014, 99, 873-880.	1.7	32
77	Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood, 2014, 124, 1062-1069.	0.6	340
78	CXCR5-Mediated Shaping of the Lymphoid Follicle in Chronic Lymphocytic Leukemia. Cancer Discovery, 2014, 4, 1374-1376.	7.7	1
79	Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis. Annals of Hematology, 2014, 93, 797-802.	0.8	10
80	Antitumoral Activity of Lenalidomide in In Vitro and In Vivo Models of Mantle Cell Lymphoma Involves the Destabilization of Cyclin D1/p27KIP1 Complexes. Clinical Cancer Research, 2014, 20, 393-403.	3.2	24
81	Unlocking New Therapeutic Targets and Resistance Mechanisms in Mantle Cell Lymphoma. Cancer Cell, 2014, 25, 7-9.	7.7	17
82	B cell activation through <scp>CD</scp>40 and <scp>IL</scp>4R ligation modulates the response of chronic lymphocytic leukaemia cells to <scp>BAFF</scp> and <scp>APRIL</scp>. British Journal of Haematology, 2014, 164, 570-578.	1.2	32
83	Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. Genome Research, 2014, 24, 212-226.	2.4	175
84	Recurrent mutations ofNOTCHgenes in follicular lymphoma identify a distinctive subset of tumours. Journal of Pathology, 2014, 234, 423-430.	2.1	59
85	Disruption of Follicular Dendritic Cellsâ€“Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib). Clinical Cancer Research, 2014, 20, 3458-3471.	3.2	24
86	Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. Blood, 2014, 123, 3790-3796.	0.6	97
87	Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption. Haematologica, 2014, 99, e231-e234.	1.7	33
88	Daratumumab, a Novel Anti-CD38 Monoclonal Antibody Shows Anti-Tumor Activity in CLL and hampers Leukemia-Microenvironment Interactions. Blood, 2014, 124, 4680-4680.	0.6	5
89	Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma. Oncotarget, 2014, 5, 726-739.	0.8	25
90	Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma. Oncotarget, 2014, 5, 6788-6800.	0.8	32

#	Article	IF	Citations
91	Risk of Central Nervous System (CNS) Involvement in Patients with Mantle Cell Lymphoma (MCL): Analysis of Clinico-Biological Factors in a Series of 283 Cases. Blood, 2014, 124, 1677-1677.	0.6	4
92	The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells. Haematologica, 2013, 98, 1739-1747.	1.7	39
93	Clonal evolution in chronic lymphocytic leukemia: Analysis of correlations with IGHV mutational status, NOTCH1 mutations and clinical significance. Genes Chromosomes and Cancer, 2013, 52, 920-927.	1.5	15
94	Sorafenib Inhibits Cell Migration and Stroma-Mediated Bortezomib Resistance by Interfering B-cell Receptor Signaling and Protein Translation in Mantle Cell Lymphoma. Clinical Cancer Research, 2013, 19, 586-597.	3.2	24
95	Establishment and Validation of Analytical Reference Panels for the Standardization of Quantitative BCR-ABL1 Measurements on the International Scale. Clinical Chemistry, 2013, 59, 938-948.	1.5	46
96	Refining the Diagnosis and Prognostic Categorization of Acute Myeloid Leukemia Patients with an Integrated Use of Cytogenetic and Molecular Studies. Acta Haematologica, 2013, 129, 65-71.	0.7	3
97	Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18250-18255.	3.3	488
98	Autophagy controls everolimus (RAD001) activity in mantle cell lymphoma. Autophagy, 2013, 9, 115-117.	4.3	24
99	Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood, 2013, 121, 2734-2738.	0.6	246
100	SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood, 2013, 121, 2175-2185.	0.6	129
101	Follicular Dendrytic Cells Deliver Angiogenesis Signaling To Follicular Lymphoma Cells That Is Hampered By The Pan-PI3K Inhibitor NVP-BKM120. Blood, 2013, 122, 3072-3072.	0.6	2
102	Daratumumab, a Novel Human Anti-CD38 Monoclonal antibody shows Anti-Tumor Activity In Mouse Models Of MCL, FL and CLL. Blood, 2013, 122, 378-378.	0.6	5
103	Identification of novel tumor suppressor proteases by degradome profiling of colorectal carcinomas. Oncotarget, 2013, 4, 1919-1932.	0.8	12
104	Identification of novel tumor suppressor proteases by degradome profiling of colorectal carcinomas. Oncotarget, 2013, 4, 1919-1932.	0.8	1
105	Counteracting Autophagy Overcomes Resistance to Everolimus in Mantle Cell Lymphoma. Clinical Cancer Research, 2012, 18, 5278-5289.	3.2	58
106	Molecular Subsets of Mantle Cell Lymphoma Defined by the IGHV Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features. Cancer Research, 2012, 72, 5307-5316.	0.4	231
107	Enhancement of fludarabine sensitivity by all-trans-retinoic acid in chronic lymphocytic leukemia cells. Haematologica, 2012, 97, 943-951.	1.7	17
108	Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nature Genetics, 2012, 44, 1236-1242.	9.4	525

#	Article	IF	Citations
109	Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nature Genetics, 2012, 44, 47-52.	9.4	893
110	Different distribution of NOTCH1 mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations. Genes Chromosomes and Cancer, 2012, 51, 881-889.	1.5	57
111	NOTCH1 mutations in chronic lymphocytic leukemia with trisomy 12. Genes Chromosomes and Cancer, 2012, 51, 1064-1065.	1.5	0
112	A new genetic abnormality leading to TP53 gene deletion in chronic lymphocytic leukaemia. British Journal of Haematology, 2012, 156, 612-618.	1.2	7
113	Molecular pathogenesis of mantle cell lymphoma. Journal of Clinical Investigation, 2012, 122, 3416-3423.	3.9	325
114	Daratumumab, a Novel Human Anti-CD38 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia and B-Cell Nonâ€“Hodgkin Lymphoma. Blood, 2012, 120, 3935-3935.	0.6	6
115	The Multi-Kinase Inhibitor Sorafenib Blocks Migration, BCR Survival Signals, Protein Translation and Stroma-Mediated Bortezomib Resistance in Mantle Cell Lymphoma. Blood, 2012, 120, 1647-1647.	0.6	5
116	Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature, 2011, 475, 101-105.	13.7	1,364
117	The Expression of the Endoplasmic Reticulum Stress Sensor BiP/GRP78 Predicts Response to Chemotherapy and Determines the Efficacy of Proteasome Inhibitors in Diffuse Large B-Cell Lymphoma. American Journal of Pathology, 2011, 179, 2601-2610.	1.9	57
118	Nonhepatosplenic Î³Î´ T-cell Lymphomas Represent a Spectrum of Aggressive Cytotoxic T-cell Lymphomas With a Mainly Extranodal Presentation. American Journal of Surgical Pathology, 2011, 35, 1214-1225.	2.1	120
119	Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy. Haematologica, 2011, 96, 1470-1477.	1.7	59
120	The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. Blood, 2011, 117, 1270-1279.	0.6	102
121	Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation. Leukemia Research, 2011, 35, 1276-1278.	0.4	4
122	A putative â€œhepitypeâ€•in the ATM gene associated with chronic lymphocytic leukemia risk. Genes Chromosomes and Cancer, 2011, 50, 887-895.	1.5	5
123	Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. Leukemia Research, 2011, 35, 1014-1019.	0.4	52
124	Combined analysis of levels of serum B-cell activating factor and a proliferation-inducing ligand as predictor of disease progression in patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2011, 52, 2064-2068.	0.6	16
125	Vorinostat-Induced Apoptosis in Mantle Cell Lymphoma Is Mediated by Acetylation of Proapoptotic BH3-Only Gene Promoters. Clinical Cancer Research, 2011, 17, 3956-3968.	3.2	76
126	Translocation of Nucleoside Analogs Across the Plasma Membrane in Hematologic Malignancies. Nucleosides, Nucleotides and Nucleic Acids, 2011, 30, 1324-1340.	0.4	15

#	Article	IF	Citations
127	Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. Haematologica, 2010, 95, 1317-1324.	1.7	53
128	Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood, 2010, 116, e111-e117.	0.6	141
129	In vitro and In vivo Selective Antitumor Activity of Edelfosine against Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Involving Lipid Rafts. Clinical Cancer Research, 2010, 16, 2046-2054.	3.2	87
130	NF-ÎºB as a therapeutic target in chronic lymphocytic leukemia. Expert Opinion on Therapeutic Targets, 2010, 14, 275-288.	1.5	44
131	Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma. Cancer Research, 2010, 70, 1408-1418.	0.4	429
132	Stability of Conversion Factors for BCR-ABL Monitoring -â€“ Implications for the Frequency of Validation Rounds. Blood, 2010, 116, 893-893.	0.6	16
133	Association Between EZH2 and Other Acquired Mutations In Myelofibrosis and Myelodysplastic/Myeloproliferative Neoplasms. Blood, 2010, 116, 625-625.	0.6	64
134	The Nucleoside Analogue Acadesine Exerts Antitumoral Activity and Cooperates with Conventional Agents In In Vitro and In Vivo Models of Mantle Cell Lymphoma. Blood, 2010, 116, 3918-3918.	0.6	0
135	B Cell Stimulation through BCR and CD40 Modulates the Response of Chronic Lymphocytic Leukemia Cells to BAFF and APRIL.. Blood, 2010, 116, 1361-1361.	0.6	0
136	Harmonized Testing for BCR-ABL Kinase Domain Mutations In CML: Results of a Survey and First Control Round within 28 National Reference Laboratories In Europe. Blood, 2010, 116, 894-894.	0.6	1
137	MicroRNA Expression, Chromosomal Alterations, and Immunoglobulin Variable Heavy Chain Hypermutations in Mantle Cell Lymphomas. Cancer Research, 2009, 69, 7071-7078.	0.4	78
138	SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica, 2009, 94, 1555-1562.	1.7	345
139	p65 Activity and ZAP-70 Status Predict the Sensitivity of Chronic Lymphocytic Leukemia Cells to the Selective IÎºB Kinase Inhibitor BMS-345541. Clinical Cancer Research, 2009, 15, 2767-2776.	3.2	31
140	Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: Relationship with thrombosis occurrence and JAK2 V617F allele burden. American Journal of Hematology, 2009, 84, 102-108.	2.0	116
141	Expression and mutational analyses of KIT and PDGFRâ€Î± in sarcomatoid renal cell carcinoma. Histopathology, 2009, 55, 230-232.	1.6	9
142	Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM. Blood, 2009, 114, 1563-1575.	0.6	50
143	BAFF and APRIL in Chronic Lymphocytic Leukemia: Clinico-Biological Correlates and Prognostic Significance.. Blood, 2009, 114, 1235-1235.	0.6	1
144	The Expression of the ER Stress Sensor GRP78/Bip Is a Target of R-CHOP and Bortezomib Treatments in DLBCL with Prognostic Value. A Rationale for the Use of Proteasome Inhibitors in DLBCL Patients.. Blood, 2009, 114, 3734-3734.	0.6	0

#	Article	IF	Citations
145	Early Optimization of Imatinib Therapy in Patients Newly Diagnosed with Chronic-Phase Chronic Myeloid Leukemia (CP-CML). A Study of the Spanish PETHEMA Group.. Blood, 2009, 114, 1113-1113.	0.6	0
146	Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis. Annals of Hematology, 2008, 87, 269-276.	0.8	50
147	Multiple recurrent chromosomal breakpoints in mantle cell lymphoma revealed by a combination of molecular cytogenetic techniques. Genes Chromosomes and Cancer, 2008, 47, 1086-1097.	1.5	28
148	Molecular Lymph Node Staging in Bladder Urothelial Carcinoma: Impact on Survival. European Urology, 2008, 54, 1363-1372.	0.9	40
149	Genetic Variants in Apoptosis and Immunoregulation-Related Genes Are Associated with Risk of Chronic Lymphocytic Leukemia. Cancer Research, 2008, 68, 10178-10186.	0.4	67
150	Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling. Clinical Cancer Research, 2008, 14, 6907-6915.	3.2	69
151	Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells. Haematologica, 2008, 93, 1843-1851.	1.7	20
152	Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood, 2008, 112, 3130-3134.	0.6	154
153	High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. Haematologica, 2008, 93, 207-214.	1.7	24
154	Gene expression profile and genomic changes in disease progression of early-stage chronic lymphocytic leukemia. Haematologica, 2008, 93, 132-136.	1.7	17
155	Selective Inhibition of Ĩº B Kinase Sensitizes Mantle Cell Lymphoma B Cells to TRAIL by Decreasing Cellular FLIP Level. Journal of Immunology, 2007, 178, 1923-1930.	0.4	81
156	The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia. Haematologica, 2007, 92, 308-314.	1.7	76
157	The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood, 2007, 109, 4441-4449.	0.6	184
158	Epstein-Barr Virus Negative Clonal Plasma Cell Proliferations and Lymphomas in Peripheral T-cell Lymphomas. American Journal of Surgical Pathology, 2007, 31, 1310-1322.	2.1	77
159	Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: Two cases with a different outcome. American Journal of Hematology, 2007, 82, 849-851.	2.0	33
160	Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nature Reviews Cancer, 2007, 7, 750-762.	12.8	433
161	Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. British Journal of Haematology, 2007, 136, 590-596.	1.2	75
162	BCL-2 Phosphorylation Modulates Sensitivity to the BH3-Mimetic GX15-070 (Obatoclax) and Reduces Its Synergistic Interaction with Bortezomib in Chronic Lymphocytic Leukemia Cells.. Blood, 2007, 110, 3464-3464.	0.6	1

#	Article	IF	Citations
163	JAK2 Mutations at Exon 12 and 14 in Polycythemia Vera and Idiopathic Erythrocytosis: Incidence and Correlation with Clinical Characteristics.. Blood, 2007, 110, 2532-2532.	0.6	0
164	The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood, 2006, 107, 257-264.	0.6	417
165	Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood, 2006, 107, 4563-4569.	0.6	130
166	Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. Leukemia Research, 2006, 30, 923-934.	0.4	45
167	Molecular biology in acute leukemia. Clinical and Translational Oncology, 2006, 8, 550-559.	1.2	5
168	Studies of complex Ph translocations in cases with chronic myelogenous leukemia and one with acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 2006, 166, 89-93.	1.0	12
169	Mantle cell lymphoma in Taiwan: Clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2. Pathology International, 2006, 56, 440-448.	0.6	20
170	The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis. Hepatology, 2006, 44, 44-52.	3.6	103
171	ZAP-70 Expression in Normal Pro/Pre B Cells, Mature B Cells, and in B-Cell Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2006, 12, 726-734.	3.2	50
172	Lack of Methylthioadenosine Phosphorylase Expression in Mantle Cell Lymphoma Is Associated with Shorter Survival: Implications for a Potential Targeted Therapy. Clinical Cancer Research, 2006, 12, 3754-3761.	3.2	31
173	Gene Expression Profiling of Acute Myeloid Leukemia with Translocation t(8;16)(p11;p13) and MYST3-CREBBP Rearrangement Reveals a Distinctive Signature with a Specific Pattern of HOX Gene Expression. Cancer Research, 2006, 66, 6947-6954.	0.4	127
174	Obatoclax (GX15-070) Is a Potent Antagonist of Constitutive Mcl-1/Bak Interactions in Intact Mitochondrial Membrane and Synergizes with Bortezomib in Mantle Cell Lymphoma.. Blood, 2006, 108, 832-832.	0.6	5
175	Tissue Factor and Soluble Markers of Platelet and Endothelial Activation in Essential Thrombocythemia: Relationship with Thrombosis and JAK2 V617F Mutation Status.. Blood, 2006, 108, 2707-2707.	0.6	0
176	FLT3 Mutations in a Large Series of Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Anthracycline Monochemotherapy.. Blood, 2006, 108, 2348-2348.	0.6	0
177	Essential Thrombocythemia in Young Individuals: Frequency and Risk Factors for Vascular Events and Evolution to Myelofibrosis in 126 Patients.. Blood, 2006, 108, 3598-3598.	0.6	0
178	Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives. Haematologica, 2006, 91, 11-6.	1.7	135
179	Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica, 2006, 91, 169-75.	1.7	199
180	Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica, 2006, 91, 895-902.	1.7	63

#	Article	IF	Citations
181	Lack of association of CYP3A4-V polymorphism with the risk of treatment-related leukemia. Leukemia Research, 2005, 29, 595-597.	0.4	10
182	Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature Genetics, 2005, 37, 391-400.	9.4	1,710
183	Reply to Schmidt ?MYST3/CREBBP (MOZ/CBP) andCREBBP/MYST3(CBP/MOZ) Transcripts in AML with t(8;16)(p11;p13)?. Genes Chromosomes and Cancer, 2005, 42, 209-209.	1.5	0
184	Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. Journal of Pathology, 2005, 205, 507-513.	2.1	73
185	CDK4 and MDM2 Gene Alterations Mainly Occur in Highly Proliferative and Aggressive Mantle Cell Lymphomas with Wild-type INK4a/ARF Locus. Cancer Research, 2005, 65, 2199-2206.	0.4	93
186	Diffuse Large B-Cell Lymphoma: Clinical and Biological Characterization and Outcome According to the Nodal or Extranodal Primary Origin. Journal of Clinical Oncology, 2005, 23, 2797-2804.	0.8	253
187	Allogeneic Stem-Cell Transplantation May Overcome the Adverse Prognosis of Unmutated VH Gene in Patients With Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2005, 23, 3433-3438.	0.8	137
188	Survivin expression in the progression of chronic myeloid leukemia: A sequential study in 16 patients. Leukemia and Lymphoma, 2005, 46, 717-722.	0.6	26
189	Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene, 2005, 24, 7213-7223.	2.6	202
190	Severe Myelodysplasia with Monosomy 7 Developing during Imatinib Treatment of Philadelphia-Positive Chronic Myeloid Leukemia: Two Cases Evolving with Different Outcome.. Blood, 2005, 106, 4861-4861.	0.6	0
191	c-FLIP Level Determines the Sensitivity of Mantle Cell Lymphoma Cells to TRAIL-Induced Apoptosis Following Inhibition of NFkB Signalling or Proteasome Activity.. Blood, 2005, 106, 4820-4820.	0.6	0
192	Gene Expression Signature of Acute Myeloid Leukemia (AML) with T(8;16)(P11;P13) and MYST3-CREBBP Rearrangement: A Microarray Study Validated by Multiple Real-Time PCR.. Blood, 2005, 106, 3009-3009.	0.6	0
193	Quantitative Assessment of PML-RARa and BCR-ABL by Two Real-Time PCR Instruments: Multiinstitutional Laboratory Trial. Clinical Chemistry, 2004, 50, 1088-1092.	1.5	8
194	Cytotoxic Effects on B Lymphocytes Mediated by Reactive Oxygen Species. Current Pharmaceutical Design, 2004, 10, 841-853.	0.9	10
195	Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes. Oncogene, 2004, 23, 8941-8949.	2.6	23
196	Type IMOZ/CBP (MYST3/CREBBP)is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation. Genes Chromosomes and Cancer, 2004, 40, 140-145.	1.5	72
197	Nuclear Survivin Expression in Mantle Cell Lymphoma Is Associated with Cell Proliferation and Survival. American Journal of Pathology, 2004, 164, 501-510.	1.9	92
198	Increased incidence of acute myeloid leukemia after liver transplantation? Description of three new cases and review of the literature1. Transplantation, 2004, 77, 311-313.	0.5	22

#	Article	IF	Citations
199	Clonal T-cell Populations and Increased Risk for Cytotoxic T-cell Lymphomas in B-CLL Patients. American Journal of Surgical Pathology, 2004, 28, 849-858.	2.1	67
200	The History of 34 Errors Identified in 874 Patients Analyzed at Weekly Clinical-Pathological Meetings in Two Institutions over 22 Years (1982â€“2004).. Blood, 2004, 104, 5287-5287.	0.6	1
201	Gene Expression Profile of Acute Myeloid Leukemia (AML) with t(8;16)(p11;p13) and MYST3/CREBBP Rearrangement.. Blood, 2004, 104, 2054-2054.	0.6	0
202	Equilibrative Nucleoside Transporter-2 (ENT2) Protein Correlates with Ex-Vivo Sensitivity to Fludarabine in Chronic Lymphocytic Leukemia (CLL)-Cells.. Blood, 2004, 104, 2079-2079.	0.6	0
203	Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis. Experimental Hematology, 2003, 31, 204-210.	0.2	39
204	Mechanism of action and resistance to monoclonal antibody therapy. Seminars in Oncology, 2003, 30, 424-433.	0.8	84
205	Chimeric BCR/ABL gene detected by fluorescence in situ hybridization in three new cases of Philadelphia chromosome-negative chronic myelocytic leukemia. Cancer Genetics and Cytogenetics, 2003, 141, 114-119.	1.0	16
206	High levels of chromosomal imbalances in typical and small-cell variants of T-cell prolymphocytic leukemia. Cancer Genetics and Cytogenetics, 2003, 147, 36-43.	1.0	30
207	Routine use of immunophenotype by flow cytometry in tissues with suspected hematological malignancies. , 2003, 56B, 8-15.		29
208	ZAP-70 Expression as a Surrogate for Immunoglobulin-Variable-Region Mutations in Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2003, 348, 1764-1775.	13.9	1,194
209	Cadherin-13, a Mediator of Calcium-Dependent Cell-Cell Adhesion, Is Silenced by Methylation in Chronic Myeloid Leukemia and Correlates With Pretreatment Risk Profile and Cytogenetic Response to Interferon Alfa. Journal of Clinical Oncology, 2003, 21, 1472-1479.	0.8	90
210	Incidence and Clinical Significance of Bcl-2 / IgH Rearrangements in Follicular Lymphoma. Leukemia and Lymphoma, 2003, 44, 71-76.	0.6	37
211	Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood, 2003, 101, 78-84.	0.6	356
212	Elevated Production of Interleukin-6 Is Associated With a Lower Incidence of Disease-Related Ischemic Events in Patients With Giant-Cell Arteritis. Circulation, 2003, 107, 2428-2434.	1.6	169
213	Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. Blood, 2003, 101, 2328-2334.	0.6	101
214	Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. Blood, 2003, 101, 3674-3680.	0.6	130
215	Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood, 2003, 103, 1237-1243.	0.6	395
216	Tyrosinase mRNA in Blood of Patients With Melanoma Treated With Adjuvant Interferon. Journal of Clinical Oncology, 2002, 20, 4032-4039.	0.8	53

#	Article	IF	Citations
217	Different clinical value of minimal residual disease after autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Blood, 2002, 99, 1873-1874.	0.6	36
218	Involvement of protein kinase C and phosphatidylinositol 3â€“kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells. Blood, 2002, 99, 2969-2976.	0.6	131
219	CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. Blood, 2002, 100, 4602-4608.	0.6	67
220	Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. Blood, 2002, 100, 1810-1816.	0.6	108
221	Genetic Imbalances in Progressed B-Cell Chronic Lymphocytic Leukemia and Transformed Large-Cell Lymphoma (Richter's Syndrome). American Journal of Pathology, 2002, 161, 957-968.	1.9	86
222	CD34+-enrichedâ€“CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders. Experimental Hematology, 2002, 30, 824-830.	0.2	23
223	Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. British Journal of Haematology, 2002, 119, 976-984.	1.2	163
224	Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood, 2001, 98, 2771-2777.	0.6	184
225	Rapid Diagnosis of Acute Promyelocytic Leukemia by Analyzing the Immunocytochemical Pattern of the PML Protein With the Monoclonal Antibody PG-M3. American Journal of Clinical Pathology, 2000, 114, 786-792.	0.4	25
226	In Vitro Evaluation of Fludarabine in Combination With Cyclophosphamide and/or Mitoxantrone in B-Cell Chronic Lymphocytic Leukemia. Blood, 1999, 94, 2836-2843.	0.6	168
227	Title is missing!. Molecular and Cellular Biochemistry, 1999, 191, 229-234.	1.4	11
228	Î±-thalassaemia due to a single codon deletion in the Î±-1-globin gene. Computational structural analysis of the new Î±-chain variant. Human Mutation, 1998, 11, 412-412.	1.1	18
229	Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of Bâ€chronic lymphocytic leukaemia cells. British Journal of Haematology, 1998, 100, 142-146.	1.2	81
230	Aspirin and Salicylate Induce Apoptosis and Activation of Caspases in B-Cell Chronic Lymphocytic Leukemia Cells. Blood, 1998, 92, 1406-1414.	0.6	182
231	Aspirin and Salicylate Induce Apoptosis and Activation of Caspases in B-Cell Chronic Lymphocytic Leukemia Cells. Blood, 1998, 92, 1406-1414.	0.6	2
232	Involvement of CED-3/ICE Proteases in the Apoptosis of B-Chronic Lymphocytic Leukemia Cells. Blood, 1997, 89, 3378-3384.	0.6	88
233	FIRST DESCRIPTION OF A FRAMESHIFT MUTATION IN THE Î± 1 â€GLOBIN GENE ASSOCIATED WITH Î±â€THALASSAEMIA. British Journal of Haematology, 1997, 98, 47-50.	1.2	14
234	Independent origin of single and double mutations in the human glucose 6-phosphate dehydrogenase gene. , 1996, 8, 311-318.		18

#	Article	IF	Citations
235	Surface adenosine deaminase. Human Immunology, 1995, 42, 265-273.	1.2	16
236	Chronic nonspherocytic hemolytic anemia (CNSHA) and glucose 6 phosphate dehydrogenase (G6PD) deficiency in a patient with familial amyloidotic polyneuropathy (FAP). Human Genetics, 1989, 81, 161-164.	1.8	8
237	Combined assay of adenosine deaminase, purine nucleoside phosphorylase, and lactate dehydrogenase in the early clinical evaluation of B-chronic lymphocytic leukemia. American Journal of Hematology, 1988, 27, 157-162.	2.0	13